Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.
Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.
Boston Scientific's Reliance 4-Front defibrillation leads.
The issue, associated with calcification, can make these devices less effective over time. The Heart Rhythm Society shared a detailed analysis of the situation.
The newly approved device captures electrocardiogram, photoplethysmogram and seismocardiogram signals at the same time. It can also be paired with advanced AI models to monitor patients for specific conditions.
Former ACC president Kim Allan Williams Sr., MD, shared his experience bringing helpful heart screenings to low-income neighborhoods. "You've got to be willing to go out and find where the patients are," he said.
Carmat is working to overcome financial struggles that forced it to suspend new device implants through the end of August. Even with its future in limbo, the company remains focused on moving forward.
AdventHealth Orlando Hospital is ranked No. 1 on the 2025 U.S. News Honor Roll for the best hospitals in America list.
Hospitals are awarded Honor Roll points if they rank in one or more of the 15 specialties that U.S. News evaluates, and in one or more of the 22 procedures or conditions for patient outcomes.
The FDA previously shared an early alert about this issue, but it was still reviewing the situation at the time. The new recall covers a total of more than 11,000 devices.
